NTHI

$9.06+0.09 (+1.00%)

Market OpenAs of Mar 17, 7:01 PM UTC

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$9.06
Potential Upside
5%
Whystock Fair Value$9.51
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$220.78M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.11

Recent News

Simply Wall St.
Dec 2, 2025

Insider Buys Additional US$185k In NeOnc Technologies Holdings Stock

Investors who take an interest in NeOnc Technologies Holdings, Inc. ( NASDAQ:NTHI ) should definitely note that the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Nov 14, 2025

With 61% ownership, NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) insiders have a lot riding on the company's future

Key Insights Insiders appear to have a vested interest in NeOnc Technologies Holdings' growth, as seen by their...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Yahoo Finance Video
Jul 30, 2025

AI and biotech take on brain cancer

You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (NTHI), about how the company defied a tough market to go public, secure a $50 million partnership in the Middle East, and join the Russell Microcap Index. Heshmatpour explains NeOnc’s focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC’s medical school, and how global clinical trials are expanding the company’s reach. The conversation also includes how AI and quantum computing could transform the biotech industry. It’s a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Jun 26, 2025

NeOnc Technologies Holdings Insiders Lose Out As Stock Sinks To US$3.72

The recent 22% drop in NeOnc Technologies Holdings, Inc.'s ( NASDAQ:NTHI ) stock could come as a blow to insiders who...

BEARISH
Negative press. News cycle fixated on risk factors or misses.